Potential new treatment for cocaine addiction

A promising new drug treatment for cocaine addiction has been discovered by researchers. The experimental therapy, which involves administering a drug currently used in cancer therapy trials, treats cocaine addiction by inhibiting memories responsible for cravings.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Abstract c-Met and VEGFR-2 have attracted interest as novel targets for treatment of various cancers. Aiming to develop potent dual c-Met and VEGFR-2 inhibitors, a series of pyrrolo[1,2-f][1,2,4]triazine derivatives were designed and synthesized. The majority of target compounds exhibited potent antiproliferative effect against c-Met addictive cancer cell lines with IC50 values ranged from 1.2 to 24.6 nM, especially 27a. In-depth studies demonstrated 27a has great selectivity to c-Met and VEGFR-2, and potent inhibitory activity against them (IC50 of 2.3 ± 0.1 nM and 5.0 ± 0.5 nM). Furth...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
Authors: Li T, Le A Abstract KEY POINTS: Dysregulation of the TCA cycle and glutamine addiction are characteristic features of glutamine metabolism in cancers. Targeting glutamine metabolism in cancer includes inhibition of glutaminolysis by glutaminase inhibitors, combination therapy, knockdown of c-MYC, inhibition of GDH, depletion of glutamine supply, inhibition of glutamine uptake, and usage of glutamine analogs. Transaminase upregulation and targeting amino acid synthesis have potential for cancer therapy. PMID: 29946773 [PubMed - in process]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Abstract Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders. The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to op...
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
Contributor : Andreas EgerSeries Type : Expression profiling by arrayOrganism : Homo sapiensComplex three-dimensional (3D) in vitro model systems that recapitulate human tumor biology are essential to better understand the pathophysiology of the disease and to aid in the discovery of novel anti-cancer therapies. 3D organotypic cultures exhibit intercellula communication, nutrient and oxygen gradients, and cell polarity that is lacking in traditional two-dimensional (2D) monolayer cultures. In the present study, we could demonstrate that 2D and 3D cancer models exhibit different drug sensitivities towards both targeted inhi...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Loss-of-function mutations in the CBP/CREBBP gene, which encodes a histone acetyltransferase (HAT), are present in a variety of human tumors, including lung, bladder, gastric, and hematopoietic cancers. Consequently, development of a molecular targeting method capable of specifically killing CBP-deficient cancer cells would greatly improve cancer therapy. Functional screening of synthetic-lethal genes in CBP-deficient cancers identified the CBP paralog p300/EP300. Ablation of p300 in CBP-knockout and -deficient cancer cells induced G1/S cell-cycle arrest, followed by apoptosis. Genome-wide gene expression analysis revealed...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Finding Synthetic Lethal Interactions through Functional Genomics: Poster Presentations - Proffered Abstracts Source Type: research
Purpose of review: The present review introduces recent outstanding progress pertaining to Enhancer of zeste homolog 2 (EZH2), especially regarding its mode of action as a master regulator of chromatin, and provides molecular-based evidence for targeting EZH2 in cancer therapy. We discuss the active development of small molecules targeting the enzymatic activity of EZH2/polycomb repressive complex 2 (PRC2). Recent findings: Genetic, transcriptional, and posttranscriptional dysregulation of EZH2 is frequently observed in many cancer types. EZH2 promotes tumorigenesis by altering the expression of numerous tumor suppressor ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research
Publication date: 10 July 2017 Source:Cancer Cell, Volume 32, Issue 1 Author(s): Surendra K. Shukla, Vinee Purohit, Kamiya Mehla, Venugopal Gunda, Nina V. Chaika, Enza Vernucci, Ryan J. King, Jaime Abrego, Gennifer D. Goode, Aneesha Dasgupta, Alysha L. Illies, Teklab Gebregiworgis, Bingbing Dai, Jithesh J. Augustine, Divya Murthy, Kuldeep S. Attri, Oksana Mashadova, Paul M. Grandgenett, Robert Powers, Quan P. Ly, Audrey J. Lazenby, Jean L. Grem, Fang Yu, José M. Matés, John M. Asara, Jung-whan Kim, Jordan H. Hankins, Colin Weekes, Michael A. Hollingsworth, Natalie J. Sarkova, Aaron R. Sasson, Jason B. Flemin...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Conclusion: As a minimally metabolized radiotracer, [18F]4F-Gln is a marker of glutamine pool size and can infer changes in tumor glutaminolysis with glutaminase inhibition through estimation of DV and T:B ratios. These findings indicate promise for [18F]4F-Gln as a biomarker to assess glutaminase-directed therapy. Research Support: This study is supported by funding from Susan G. Komen Foundation Grant SAC140060 (DM), Department of Energy Grant DE-SE0012476 (DM and RHM), R21-CA-198563 (RZ) and R01CA211337 (DM and RZ).
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Radiotherapy and Monitoring Therapy Source Type: research
Conclusions: We have successfully synthesized three new PatA analogs with potent anti-leukemia activities. These compounds hold promise for application to cancers with the right biological context, such as CLL, in which the leukemia cells are addicted to the sustained expression of short-lived oncoproteins for survival.Citation Format: Rong Chen, Mingzhao Zhu, Yuling Chen, Wesley Skillern, Qun Qin, William G. Wierda, Kenneth G. Hull, Daniel Romo, William Plunkett. Novel pateamine A analogs to target pro-survival proteins in chronic lymphocytic leukemia. [abstract]. In: Proceedings of the AACR Special Conference on Translat...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Small Molecule Drugs Selectively Targeting Translation Specialized for the Cancer Cell Source Type: research
Detection of genetic alterations mastering lung cancer biology provides suitable targets for personalized anti-cancer therapy. In non-small cell lung cancer (NSCLC), activating mutations of EGFR, HER2, BRAF, MET, as well as gene fusions involving ALK, ROS1, RET, the members of NTRK and FGFR families, govern the oncogenic potential of malignant cells. The detection and targeting of those genetic abnormalities have demonstrated major improvement in clinical outcomes. Altogether, genetic alterations suitable of targeted treatments are currently detected in 30-40% of advanced non-small cell lung cancers (mainly adenocarcinomas...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research
More News: Addiction | Cancer | Cancer & Oncology | Cancer Therapy | Science